But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

By Andrew Silver SHANGHAI (Reuters) -Drug research and development firms in China including WuXi AppTec and WuXi Biologics ...

China now offers a dizzyingly abundant source of innovative, high-quality therapies at—by pharma standards—reasonable prices.

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Ben Simpfendorfer, Partner at Oliver Wyman, explains why having a multi-country manufacturing presence, including China, is ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office ...

"Over the past 16 years, Tsinghua University and Bayer have forged a trusted and synergistic partnership that has ...

It looks like U.S. pharmaceutical companies are looking to China for drugs. U.S. drugmakers are licensing molecules from ...

China has taken a series of actions in the past week on counter-narcotics, in a sign of cooperation with U.S. demands for ...